US equities |
MU $953.19 ▼-3.62% NVDA $228.52 ▲+0.97% META $762.50 ▲+2.63% AAPL $341.27 ▲+0.09% MSFT $543.45 ▲+0.43% SNDK $1,482.33 ▼-0.34% AMD $605.53 ▲+1.90% SPCX $156.54 ▼-4.21%
FinancialContent

Xilio Therapeutics, Inc. - Common Stock (NQ:XLO)

9.220 +0.145 (+1.60%)
Delayed Quote Updated: 4:00 PM EDT, Oct 13, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Xilio Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
News headline image
12 Health Care Stocks Moving In Monday's After-Market Session ↗
 
Via Benzinga
News headline image
Xilio Therapeutics Announces Pipeline and Business Updates and First Quarter 2025 Financial Results
From Xilio Therapeutics, Inc.
Via GlobeNewswire
News headline image
Xilio Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Xilio Therapeutics, Inc.
Via GlobeNewswire
News headline image
Xilio Therapeutics to Present Updated Phase 2 Data for Vilastobart, a Tumor-Activated, Fc-Enhanced Anti-CTLA-4, in Combination with Atezolizumab in Patients with Microsatellite Stable Colorectal Cancer at the 2025 ASCO Annual Meeting
From Xilio Therapeutics, Inc.
Via GlobeNewswire
News headline image
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Xilio Therapeutics, Inc.
Via GlobeNewswire
News headline image
Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2024 Financial Results
From Xilio Therapeutics, Inc.
Via GlobeNewswire
News headline image
Xilio Therapeutics to Present at TD Cowen 45th Annual Health Care Conference
From Xilio Therapeutics, Inc.
Via GlobeNewswire
News headline image
Unusual volume stocks in Friday's session ↗
Join us as we delve into today's session and uncover the stocks that are standing out with unusual volume. 
Via Chartmill
News headline image
The trading volume of these stocks is deviating from the norm in today's session. ↗
The trading volume of these stocks is deviating from the norm in today's session. 
Via Chartmill
News headline image
Keep an eye on the top gainers and losers in Wednesday's session. ↗
Keep an eye on the top gainers and losers in Wednesday's session, as they reflect the most notable price movements. 
Via Chartmill
News headline image
These stocks are the most active in today's session ↗
Discover the most active stocks in Wednesday's session. Stay informed about the stocks that are generating the most trading volume! 
Via Chartmill
News headline image
Nasdaq Edges Higher; CVS Health Shares Jump Following Upbeat Earnings ↗
 
Via Benzinga
News headline image
Let's have a look at the top gainers and losers in the middle of the day of today's session. ↗
Here are the top movers in Wednesday's session, showcasing the stocks with significant price changes. 
Via Chartmill
News headline image
Crude Oil Down Over 2%; Upstart Shares Jump Following Earnings ↗
 
Via Benzinga
News headline image
Traders are paying attention to the gapping stocks in Wednesday's session. ↗
Let's have a look at what is happening on the US markets on Wednesday. Below you can find the gap up and gap down stocks in today's session. 
Via Chartmill
News headline image
Why Is Nano-Cap Cancer-Focused Xilio Therapeutics Stock Trading Over 100% On Wednesday? ↗
AbbVie and Xilio partner to develop tumor-activated immunotherapies. Xilio's pipeline includes masked T cell engagers for prostate, gastric, and lung cancers. 
Via Benzinga
News headline image
Dow Dips Over 300 Points; US Inflation Increases More Than Expected ↗
 
Via Benzinga
Topics Economy Stocks
News headline image
Wednesday's pre-market session: top gainers and losers ↗
As we await the opening of the US market on Wednesday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment. 
Via Chartmill
News headline image
Xilio Therapeutics Announces Multiple Masked T Cell Engager Programs
From Xilio Therapeutics, Inc.
Via GlobeNewswire
News headline image
AbbVie and Xilio Therapeutics Announce Collaboration and Option Agreement to Develop Novel Tumor-Activated Immunotherapies
From Xilio Therapeutics, Inc.; AbbVie Inc.
Via GlobeNewswire
News headline image
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Xilio Therapeutics, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Xilio Therapeutics Announces Initial Phase 2 Data for Vilastobart (XTX101), a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Metastatic Microsatellite Stable Colorectal Cancer
From Xilio Therapeutics, Inc.
Via GlobeNewswire
News headline image
Xilio Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Xilio Therapeutics, Inc.
Via GlobeNewswire
News headline image
Xilio Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Xilio Therapeutics, Inc.
Via GlobeNewswire
News headline image
Why FedEx Shares Are Trading Higher By Around 9%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
Xilio Therapeutics to Present Initial Phase 2 Data for Vilastobart (XTX101), a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Metastatic Microsatellite Stable Colorectal Cancer at ASCO GI
From Xilio Therapeutics, Inc.
Via GlobeNewswire
News headline image
Xilio Therapeutics Appoints Caroline Hensley as Chief Legal Officer
From Xilio Therapeutics, Inc.
Via GlobeNewswire
News headline image
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Xilio Therapeutics, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
 
Via Benzinga
< Previous 1 2 3 4 5 6 7 Next >